Daewoong Pharmaceutical’s self-developed botulinum toxin product "Navota" has entered the halal market and is accelerating its move as a global brand.
Daewoong Pharmaceutical said on Dec. 19 that it has recently obtained an item approval for its product Nabota in the halal countries of the United Arab Emirates and Indonesia.
The UAE Ministry of Health and the Indonesian Food and Drug Administration (Badan Pengawas Obat dan Makanan) issued the item approval for Nabota's treatment of frown lines.
Nabota became the first Korean botulinum toxin product to win item licenses in the United Arab Emirates and Indonesia, further cementing its presence in the Middle East and Asian markets following the United States, Europe and Canada.
The United Arab Emirates, in particular, is the first Middle East country for Nabota to enter, and Daewoong plans to use Nabota as its bridgehead to gain its permission from the rest of the Middle East.
"In addition to the continued growth of the drug market, the UAE is a hub country in the Middle East and Indonesia is the fourth largest population in the world and has great potential for growth," said Park Sung-soo, head of Nabotas business division at Daewoong Pharmaceutical.
"In 2020, we will further expand Nabota's influence in the global market by strengthening its presence in developed countries and allowing new market," he added.
